In the digestive system, GLP-1 reduces appetite, slows stomach emptying and changes how gut muscles contract
The FDA-approved prescribing information recommends rotating injection sites with each dose to reduce the risk of lipodystrophy and injection site reactions
Head-to-head clinical evidence SURPASS-2: Mounjaro vs Ozempic in type 2 diabetes The SURPASS-2 trial, published in the New England Journal of Medicine, directly compared tirzepatide with semaglutide 1 mg (the standard Ozempic dose) in 1,879 people with type 2 diabetes over 40 weeks
#Pharmacy #RegulatoryAffairs #Pharmaceuticals #WeightLoss #GLP1 #Healthcare #Innovation #EliLilly Eli Lilly's Orforglipron: A Promising Obesity Treatment Option Eli Lilly's Orforglipron: A Game-Changer in Obesity Treatment
That familiar approach is understandable, but it hides a cost
These units were confiscated by the FDA on April 9, 2025, and an investigation is underway in collaboration with Novo Nordisk, the pharmaceutical company behind Ozempic